Page 197 - Read Online

Saneto. J Transl Genet Genom 2020;4:384-428 I http://dx.doi.org/10.20517/jtgg.2020.40 Page 425

269. Barel O, Malicdan MCV, Ben-Zeev B, Kandel J, Pri-Chen H, et al. Deleterious variants in TRAK1 disrupt mitochondrial movement and
cause fatal encephalopathy. Brain 2017;140:568-81.
270. Sagie S, Lerman-Sagie T, Maljevic S, Yosovich K, Detert K, et al. Expanding the phenotype of TRAK1 mutations: hyperplexia and
refractory status epilepticus. Brain 2018;141:e55.
271. Janer A, Prudent J, Paupe V, Fahiminya S, Majewski J, et al. SLC26A46 is required for mitochondrial lipid homeostasis and cristae
maintenance and is responsible for Leigh syndrome. EMBO Mol Med 2016;8:1019-38.
272. Abrams AJ, Hufnagel RB, Rebelo A, Zanna C, Patel N, et al. Mutations I SLC26A46, encoding a UGO1-like protein, cause an optic
atrophy spectrum disorder. Nat Genet 2015;47:926-32.
273. Abrams AJ, Fontanes F, Tan NBL, Buglo E, Campeanu IJ, et al. Insights into the genotype-phenotype correlation and molecular function
of SLC24A46. Hum Mut 2018;39:1995-2007.
274. Goswami R, Majumdar T, Dhar J, Chattopadhyay S, Bandyopadhyay SK, et al. Viral degradasome hijacks mitochondria to suppress
innate immunity. Cell Res 2013;23:1025-42.
275. Shahni R, Cale CM, Anderson G, Osellame LD, Hambleton S, et al. Signal transducer and activator of transcription 2 deficiency is a
novel disorder of mitochondrial fission. Brain 2015;138:2834-46.
276. Anding AL, Wang C, Chang TK, Sliter DA, Powers CM, et al. VPS13D encodes a ubiquitin-binding protein that is required for the
regulation of mitochondrial size and clearance. Curr Biol 2018;28:287-95.
277. Soeng E, Insolera R, Dulovic M, Kamsteeg EJ, Trinh J, et al. Mutations in VPS13D lead to a new recessive ataxia with spasticity and
mitochondrial defects. Ann Neurol 2018;83:1075-88.
278. Kumar N, Leonzino M, Hancock-Cerutti W, Horenkamp FA, Li Q, et al. VPS13A and VPS13C are lipid transport proteins differentially
localized at ER contact sites. J Cell Biol 2018;217:3625-39.
279. Gai X, Ghezzi D, Johnson MA, Biagosch CA, Shamseldin HE, et al. Mutations in FBXL4 encoding a mitochondrial protein, cause early
onset mitochondrial encephalopathy. Am J Hum Genet 2013;93:482-95.
280. Sabouny R, Wong R, Lee-Glover L, Greenway SC, Sinasac DS, et al. Characterization of the C584R variant in the mtDNA depletion
syndrome gene FBXL4, reveals a novel role for FBXL4 as a regulator of mitochondrial fusion. Biochim Biophys Acta Mol Basis of Dis
2019;1865:165536.
281. Huemer M, Darall D, Schossig A, Abdenur JE, Al Jasmi F, et al. Clinical, morphological, biochemical, imaging and outcome parameters
in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutations. J Inherit Metab Dis 2015;38:905-14.
282. Mandel H, Saita S, Edvardson S, Jalas C, Shaag A, et al. Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and
3-methylglutaconic aciduria. J Med Genet 2016;53:690-6.
283. Horga A, Bugiardine E, Manole A, Bremner F, Jaunmuktane Z, et al. Autosomal dominant optic neuropathy and cataract “plus” phenotype
including axonal neuropathy. Neurol Genet 2019;5:e322.
284. Costeff H, Gadoth N, Apter N, Prialnic M, Savir H. A familial syndrome of infantile optic atrophy, movement disorder, and spastic
paraplegia. Neurology 1989;39:595-7.
285. Gaier ED, Sahai I, Wiggs JL, McGeeney B, Hoffman J, et al. Novel homozygous OPA3 mutation in an Afghani family with
3-methyglutaconic aciduria type III and optic atrophy. Ophthalmic Genet 2019;40:570-3.
286. Nazli A, Safdar A, Saleem A, Akhtar M, Brady LI, et al. A mutation in the TMEM65 gene results in mitochondrial myopathy with severe
neurological manifestations. Eur J Hum Genet 2017;25:744-51.
287. Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B, et al. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth
syndrome. Biochem Biophys Res Commun 2000;279:378-82.
288. Clarke SLN, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, et al. Barth syndrome. Orph J Rare Dis 2013;8:23.
289. Nishino I. New congenital muscular dystrophy due to CHKB mutations. Rinsho Shinkeigaku 2013;53:1112-3.
290. Marchet S, Invernizzi F, Blasevich F, Bruno V, Dusi S, et al. Alteration of mitochondrial membrane inner potential in three Italian patients
with megaconial congenital muscular dystrophy carrying new mutations in CHKB gene. Mitochondrion 2019;47:24-9.
291. Wortmann SB, Vaz FM, Gardeitchik T. Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial functions and
intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 2012;44:797-802.
292. Mancuso DJ, Sims HF, Han X, Jenkins CM, Guan SP, et al. Genetic ablation of calcium-independent phospholipase A2 gamma leads to
alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetics phenotype. J Biol Chem
2007;282:34611-22.
293. Shukla A, Saneto RP, Hebbar M, Mirzaa G, Girisha KM. A neurodegerative mitochondrial disease phenotype due to biallelic loss-of-
function variants in PNPLA8 encoding calcium-independent phospholipase A2g. Am J Med Genet 2018;176A:1232-7.
294. Yagi M, Uchiumi T, Takazaki S, Okuno B, Nomura M, et al. p.32/gC1qR is indispensable for fetal development and mitochondrial
translation: importance of its RNA-binding ability. Nucleic Acids Res 2012;40:9717-37.
295. Feichtinger RG, Olahova M, Kishita Y, Garone C, Kremer LS, et al. Biallelic C1QBP mutations cause severe neonatal-childhood-, or
later-onset cardiomyopathy associated with combined respiratory-chain deficiencies. Am J Hum Genet 2017;101:525-38.
296. Angebault C, Guichet P-O, Talmat-Amar Y, Charif M, Gerber S, et al. Recessive mutations in RTN4IP1 cause isolated and syndromic
optic neuropathies. Am J Hum Genet 2015;97:754-60.
297. Palmieri F, Scarcia P, Monne M. Diseases caused by mutations in mitochondrial carrier genes SLC25: a review. Biomolecules
2020;10:655.
298. Ortigoza-Escobar JD, Alfadhel M, Molero-Luis M, Darin N, Spiegel R, et al. Thiamine deficiency in childhood with attention to genetic
causes: survival and outcome predictors. Ann Neurol 2017;82:317-30.